Radiotheranostic host:guest pretargeting with PB-203 and PB-212
Active Project Grant Awarded Last action
- Award ID
- R37CA282650
- Recipient
-
The Research Foundation For The State University Of New York UEI M746VC6XMNH9 Part of The Research Foundation For The State University Of New York
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,414,875
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 53% complete
- Place of performance
- Stony Brook, NY 11794, USA
Award details come from USAspending.gov.
Description
- Abstract
- For monoclonal antibody(MAB)-based radiopharmaceuticals to widely impact precision nuclear medicine, strategies that both improve the convenience and reduce the radiation burden to non-target organs are urgently needed. Compared to direct-labeling strategies, pretargeting makes MAB-based nuclear IMAGING and targeted radionuclide THERAPY (TRT) safer, but IT has yet to realize its potential impact on clinical precision nuclear medicine. However, the modest successes and inherent limitations of existing pretargeting platforms have defined that a successful platform needs: 1) to be nonimmunogenic, 2) designed to be modular and tunable to any MAB and radionuclide, and 3) to avoid clearing agents. To date, no platform has met these criteria, and there remains a critical need for pretargeting strategies to improve precision nuclear medicine. The long-term goal of this proposal is to develop a host:guest pretargeting platform that utilizes curcubit[7]uril (CB7) "hosts" and adamantane (ADMA) radioligand "guests" for nuclear IMAGING and TRT with elementally- matched 203PB (IMAGING) and 212PB (THERAPY). CB7-ADMA host:guest pretargeting is based on nonimmunogenic molecules, uses a modular approach, and can achieve high uptake in target tissues using MAB targeting vectors with lag times that nullify the need for clearing agents. Thus, IT is hypothesized that this platform will address the shortcomings of other platforms yielding a translatable radiotheranostic approach to cancer treatment. Specific aim 1 of this proposal is the "development and evaluation of 203/212PB-labeled radioligands for pretargeting." to achieve this goal, a library of radioligands will be synthesized and evaluated in vitro as well as in vivo, optimizing the parameters of the host:guest pretargeting approach and comparing the dosimetry to a direct-labeling strategy in order to demonstrate the platform's suitability for clinical translation specific aim 2 is the "evaluation of 212PB pretargeted alpha-TRT in murine xenograft models." using the strategies for pretargeting developed in specific aim 1 as well as a fractionated dosing approach, we will establish the efficacy of our host:guest pretargeting for alpha-TRT. We will also compare the dosimetry, therapeutic index, therapeutic efficacy, and radiological toxicity to analogous approaches with directly-labeled mabs in a mouse model of cancer to validate the advantages. Successfully achieving the aims of the proposed studies will lead to the development and validation of a next generation pretargeting platform that is suitable for future translational studies and demonstrate its potential as an innovative theranostic application for TRT. The platform will be a robust, safe, and convenient alternative to direct-labeling strategies for mabs that is widely applicable to precision nuclear medicine in human disease.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $391,790 | |
| Amendment | $39,019 | |
| Amendment | $351,182 | |
| Amendment | $351,182 | |
| Amendment | $427,234 | |
| Amendment | $427,234 | |
| Original award | $427,234 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Viewpoint Molecular Targeting, Inc. | $15,988 | |
| Beckman Research Institute Of The City Of Hope | $12,035 | |
| Viewpoint Molecular Targeting, Inc. | $72,901 | |
| Beckman Research Institute Of The City Of Hope | $54,879 |
Quick answers
Who received award R37CA282650?
R37CA282650 was awarded to The Research Foundation For The State University Of New York by National Cancer Institute (National Institutes of Health) on March 19, 2024.
How much is award R37CA282650 worth?
$2,414,875 has been obligated on R37CA282650.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award